ERBB2 and triple-negative breast carcinoma: The breast cancer subtypes were distributed as follows: 430 (79.5%) patients, luminal subtype(s) (including luminal A and luminal B sub-type); 28 (5.2%), HER2-enriched subtype; and 69 (12.8%), triple-negative breast cancer (TNBC).